Nephros (NEPH) vs Polyrizon (PLRZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Polyrizon (PLRZ) has outperformed Nephros (NEPH) over the past year, gaining 23.2% versus a loss of 36.2%. Nephros is the larger company by market cap ($38.3 million vs $21.8 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEPH | PLRZ |
|---|---|---|
| Share price | $3.53 | $8.99 |
| Market cap | $38.34M | $21.83M |
| 1-day change | +7.29% | +1.33% |
| YTD return | -32.58% | +4.48% |
| 1-year return | -36.24% | +23.19% |
| 5-year return | -57.60% | — |
| P/E ratio (TTM) | 23.53 | — |
| Forward P/E | 16.81 | — |
| EPS (TTM) | $0.15 | $-4.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $18.20 |
| 52-week low | $2.66 | $2.88 |
| Distance from 52-week high | -45.02% | -50.61% |
| Analyst consensus | none | — |
| Avg. price target upside | +77.05% | — |
| Average volume | 27.59K | 60.55K |
| Shares outstanding | 10.86M | 2.43M |
| Employees | 36 | 2 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRZ has outperformed NEPH by 59.4 percentage points over the past year.
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Health Care · Medical/Dental Instruments · 36 employees
About Polyrizon
PLRZ stock →Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
Health Care · Medical/Dental Instruments · 2 employees
NEPH vs PLRZ FAQ
Which is bigger, Nephros or Polyrizon?
Nephros (NEPH) is larger, with a market capitalization of $38.34M compared with $21.83M for Polyrizon (PLRZ).
Which stock has performed better over the past year, NEPH or PLRZ?
PLRZ returned +23.19% over the past 12 months, compared with -36.24% for NEPH (price return, excluding dividends). Past performance does not predict future results.
Are Nephros and Polyrizon in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.